Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HERAMED LIMITED Capital/Financing Update 2021

Oct 13, 2021

65062_rns_2021-10-13_d01523a9-0abf-4cab-abef-4ba4516b7474.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Market Announcement

==> picture [33 x 50] intentionally omitted <==

14 October 2021

==> picture [451 x 5] intentionally omitted <==

Heramed Limited (ASX: HMD) – Trading Halt

Description

The securities of Heramed Limited (‘HMD’) will be placed in trading halt at the request of HMD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 18 October 2021 or when the announcement is released to the market.

Issued by

Belinda Giles

Adviser, Listings Compliance (Perth)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

14 October 2021 ASX Limited

14 October 2021

==> picture [85 x 45] intentionally omitted <==

ASX ANNOUNCEMENT

Madeleine Green

Senior Adviser, Listings Compliance ASX Operations Level 40 Central Park 152-158 St George’s Terrace PERTH WA 6000

Via Email: [email protected]

Dear Madeleine Green

TRADING HALT REQUEST

Medical technology company, HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”) requests that the securities of the Company be placed into a trading halt of up to two trading days with immediate effect.

For the purposes of ASX Listing Rule 17.1 and in support of its request, the Company advises that:

  1. The trading halt is requested for the purposes of considering, planning and executing a capital raising.

  2. The Company requests that the trading halt remains in place until the earlier of the Company releasing an announcement regarding the capital raising or prior to the commencement of trading on Monday, 18 October 2021.

  3. The Company is not aware of any reason why the request for the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Your faithfully

Jonathan Hart

Company Secretary

-ENDS-

HeraMED Limited ACN 626 295 314 T: +61 2 7251 1888 | A: Suite 4, Level 16, 55 Clarence Street SYDNEY NSW 2000